Lilly Nederland BV has withdrawn the EU marketing authorization application (MAA) for its Janus kinase inhibitor, Olumiant (baricitinib), for use in treating adults and children with COVID-19 who require supplemental oxygen, after the European Medicines Agency said the company had not provided enough data for an approval recommendation.
Another product has been also pulled from the EMA review process: Reata Pharmaceuticals, Inc